Science says it will prioritise PRIMA and its Science Eye vision programs

Science Corporation/PRIMA retinal implant

Science Corporation announced its strategic decision to prioritize PRIMA, its acquired photovoltaic retinal implant, over Science Eye, its optogenetic gene therapy approach. PRIMA has a faster regulatory pathway to market, while Science Eye dosing will be deferred until after PRIMA reaches regulatory approval. The company views the approaches as potentially complementary for treating different aspects of vision loss.

• PRIMA prioritized due to faster market access and larger scalable patient population compared to gene therapy development timeline.
• Science Eye first-in-human dosing deferred; company notes future potential for combination therapy where late-stage patients could receive both via single wearable interface.
• Rationale: PRIMA excels at foveal (high-resolution central vision) restoration; Science Eye targets peripheral vision loss; future strategy would combine strengths.